Optimizing Outcomes for Adults with Spinal Muscular Atrophy: Patient-Centric Strategies for the Interprofessional Treatment Team

• Examine the genetic etiology, pathophysiology, and clinical phenotypes of spinal muscular atrophy (SMA) in adult patients.
• Evaluate unique clinical challenges faced by adults with SMA, emphasizing key distinctions from pediatric SMA.
• Appraise completed, ongoing, and planned clinical trial data for novel SMA disease-modifying therapies (DMTs) in adult patients, with a focus on FDA-approved agents.
• Identify how adaptive SMA therapeutic strategies incorporating novel DMTs can fulfill unmet needs and optimize outcomes in adult patients.
• Use real-world patient cases to design evidence-supported treatment plans for adults with SMA, highlighting the critical importance of patient engagement and shared decision making.

Supported through an independent educational grant from Genentech.

It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.

CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Planners/Faculty:
Vanessa Battista, RN, MS, CPNP-PC, CHPPN–has disclosed that she was on the speakers bureau for Clinical Care Options and was an advisor or consultant to Biogen and Novartis.
Mark Huffmyer, PharmD, BCGP, BCACP–has no relevant financial relationships to disclose in relation to the content of this activity.
Claudia A. Chiriboga​, MD, MPH, FAAN​–has disclosed that she receives grants from Biogen, Biohaven, Genentech, Novartis, and Roche. She is also an advisor or consultant to Biogen, Genentech, Novartis, PTC, and Roche.

Peer Reviewer:
Erin Spencer, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.

CEC Staff/Planners:
Susan H. Gitzinger, PharmD, MPA–has no relevant financial relationships to disclose in relation to the content of this activity.
Ashley C. Lilly, MHA–has no relevant financial relationships to disclose in relation to the content of this activity.

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.